Akkermansia muciniphila in infectious disease: A new target for this next-generation probiotic?

The common gastrointestinal commensal Akkermansia muciniphila is a mucin-degrading bacterium that is greatly reduced in individuals consuming a high-fat diet. Increasing evidence from a variety of clinical and pre-clinical studies suggests that oral supplementation with Akkermansia can improve metabolic health and moderate systemic inflammation. We and others have demonstrated a role for Akkermansia administration in protection against infectious disease and the outcome from sepsis. Very recent studies have indicated the molecular mechanisms by which A. muciniphila may interact with the host to influence systemic immune-regulation and control of microbial pathogenesis. Here we consider recent studies which demonstrate the efficacy of this potential next-generation probiotic in animal models of Salmonella Typhimurium, Listeria monocytogenes and Clostridioides difficile as well as influenza virus and phlebovirus. The potential mechanisms by which A. muciniphila may influence local and systemic immune responses are discussed.

Exploring Gut Microbial Dynamics and Symbiotic Interaction in Blattella germanica Using Rifampicin.

Blattella germanica harbours two cohabiting symbiotic systems: an obligate endosymbiont, Blattabacterium, located inside bacteriocytes and vertically transmitted, which is key in nitrogen metabolism, and abundant and complex gut microbiota acquired horizontally (mainly by coprophagy) that must play an important role in host physiology. In this work, we use rifampicin treatment to deepen the knowledge on the relationship between the host and the two systems. First, we analysed changes in microbiota composition in response to the presence and removal of the antibiotic with and without faeces in one generation. We found that, independently of faeces supply, rifampicin-sensitive bacteria are strongly affected at four days of treatment, and most taxa recover after treatment, although some did not reach control levels. Second, we tried to generate an aposymbiotic population, but individuals that reached the second generation were severely affected and no third generation was possible. Finally, we established a mixed population with quasi-aposymbiotic and control nymphs sharing an environment in a blind experiment. The analysis of the two symbiotic systems in each individual after reaching the adult stage revealed that endosymbiont's load does not affect the composition of the hindgut microbiota, suggesting that there is no interaction between the two symbiotic systems in Blattella germanica.

Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance.

Globally, enteropathogenic bacteria are a major cause of morbidity and mortality.1-3 Campylobacter, Salmonella, Shiga-toxin-producing Escherichia coli, and Listeria are among the top five most commonly reported zoonotic pathogens in the European Union.4 However, not all individuals naturally exposed to enteropathogens go on to develop disease. This protection is attributable to colonization resistance (CR) conferred by the gut microbiota, as well as an array of physical, chemical, and immunological barriers that limit infection. Despite their importance for human health, a detailed understanding of gastrointestinal barriers to infection is lacking, and further research is required to investigate the mechanisms that underpin inter-individual differences in resistance to gastrointestinal infection. Here, we discuss the current mouse models available to study infections by non-typhoidal Salmonella strains, Citrobacter rodentium (as a model for enteropathogenic and enterohemorrhagic E. coli), Listeria monocytogenes, and Campylobacter jejuni. Clostridioides difficile is included as another important cause of enteric disease in which resistance is dependent upon CR. We outline which parameters of human infection are recapitulated in these mouse models, including the impact of CR, disease pathology, disease progression, and mucosal immune response. This will showcase common virulence strategies, highlight mechanistic differences, and help researchers from microbiology, infectiology, microbiome research, and mucosal immunology to select the optimal mouse model.